Private Investment Trends in Otolaryngology, 2000–2024

Introduction: Private equity and venture capital increasingly shape healthcare innovation, yet investment trends within otolaryngology remain poorly characterized. We analyzed subspecialty-specific funding patterns from 2000 to 2024 to assess how investment volume, number of funding rounds, and capital allocation across subspecialties have evolved.

Methods: We conducted a retrospective, cross-sectional analysis using Crunchbase and PrivCo to identify private equity and venture capital investments in companies developing solutions for otolaryngologic diseases from January 1, 2000 to December 31, 2024. Outcomes included total disclosed funding, number of investment rounds, funding amount per investment round, and subspecialty-specific growth rates. Independent variables included subspecialty and calendar year. Descriptive statistics, one-way ANOVA on log-transformed funding, and Poisson regression were used, with statistical significance set at p< 0.05.

Results: Private investors made 364 investments in 139 otolaryngology-related companies, totaling over $4.8 billion. Both the annual number of investments (Poisson regression p=5.75×10⁻⁵) and total funding increased over time (p=0.0167). Investment varied by subspecialty, with otology/neurotology attracting the largest share and the most rounds, followed by rhinology and sleep medicine. In contrast, laryngology, head and neck oncology and facial plastics represented a smaller proportion and had fewer rounds. Average funding per round differed by subspecialty (F(6,350)=2.26, p=0.037).

Conclusions: Private investments in otolaryngology have grown substantially, but remain concentrated in hearing loss and obstructive sleep apnea. In contrast, pediatric ENT, facial plastics, laryngology, and head and neck oncology remain underfunded despite unmet clinical needs. Addressing these gaps could help stimulate innovation in these subspecialties.